InsiderSignal.AI

InsiderSignal.ai

TRDA - Entrada Therapeutics, Inc.

Insider Sale by Dowden Nathan J (Pres, COO)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

Yesterday, Dowden Nathan J, serving as Pres, COO at Entrada Therapeutics, Inc. (TRDA), sold 15,000 shares at $15.33 per share, for a total transaction value of $229,953.00. Following this transaction, Dowden Nathan J now holds 198,588 shares of TRDA.

This sale represents a 7.00% decrease in Dowden Nathan J's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Monday, May 4, 2026 and publicly disclosed via SEC Form 4 filing on Monday, May 4, 2026, meaning the disclosure happened on the same day as the trade.

Entrada Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Dowden Nathan J

Pres, COO

Nathan J. Dowden is President and Chief Operating Officer at Entrada Therapeutics, Inc. (Nasdaq: TRDA), a clinical-stage biopharmaceutical company developing Endosomal Escape Vehicle (EEV™)-therapeutics for intracellular targets.[[1]](https://www.globenewswire.com/news-release/2024/01/03/2803161/0/en/Entrada-Therapeutics-Promotes-Nathan-J-Dowden-to-President.html)[[2]](https://www.prnewswire.com/news-releases/entrada-therapeutics-appoints-nathan-dowden-as-chief-operating-officer-300949053.html) He joined Entrada in 2019 as Chief Operating Officer and was promoted to his current expanded role effective January 1, 2024, contributing to the company's growth to over 150 employees, advancement of the lead program ENTR-601-44 into the clinic, pipeline development, and establishment of new headquarters in Boston Seaport.[[1]](https://www.globenewswire.com/news-release/2024/01/03/2803161/0/en/Entrada-Therapeutics-Promotes-Nathan-J-Dowden-to-President.html) Dowden brings over 30 years of strategy, investment, and operational experience in the healthcare sector. Prior roles include Senior Vice President of Strategy and Corporate Development at Rubius Therapeutics, where he supported evolution from early-stage discovery to clinical development; Managing Director roles at Huron Consulting Group and The Frankel Group LLC (16 years), advising on biopharma ventures, portfolio management, and commercialization; and positions at EY, Searle Pharmaceuticals, and CIGNA Healthcare. He holds an MBA from the University of Chicago Booth School of Business and a BS from the University of Connecticut.[[1]](https://www.globenewswire.com/news-release/2024/01/03/2803161/0/en/Entrada-Therapeutics-Promotes-Nathan-J-Dowden-to-President.html)[[2]](https://www.prnewswire.com/news-releases/entrada-therapeutics-appoints-nathan-dowden-as-chief-operating-officer-300949053.html)[[3]](https://theorg.com/org/entrada-therapeutics/org-chart/nathan-j-dowden)

View full insider profile →

Trade Price

$15.33

Quantity

15,000

Total Value

$229,953.00

Shares Owned

198,588

Trade Date

Monday, May 4, 2026

1 days ago

SEC Filing Date

Monday, May 4, 2026

HEALTHCAREBIOTECHNOLOGY

Discussion

Sign in to join the discussion.
Loading comments…
View news mentioning TRDA

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/6197555

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime